Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 16 de 16
Filtrar
1.
Patient Prefer Adherence ; 15: 1039-1049, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-34040357

RESUMEN

BACKGROUND: Breast cancer (BC) in young women is characterized by an unfavorable prognosis in hormone receptor-positive/HER2-negative tumors, which may be explained by low rates of tamoxifen adherence. In Mexico, up to 14% of all BC diagnoses occur in young women and no data on tamoxifen adherence has been reported. OBJECTIVE: To estimate the rate of adherence to adjuvant tamoxifen in Mexican young women with BC (YWBC). METHODS: A cross-sectional survey was conducted at the National Cancer Institute in Mexico City, among YWBC (≤40 years at diagnosis) receiving adjuvant tamoxifen. Adherence was measured subjectively, through self-reported surveys, and objectively, through medication possession ratio (MPR). Descriptive statistics were used to analyze sociodemographic characteristics. To compare associations between patients' characteristics and adherence, Chi-square test was used for categorical variables and Student's t-test or Mann-Whitney U-test for quantitative variables. RESULTS: A total of 141 YWBC receiving adjuvant tamoxifen were included. Regarding subjective adherence, 95% expressed taking tamoxifen regularly, 70% reported missing 0 doses in the past 30 days, and 71.6% reported having adverse effects. Regarding objective adherence, 74.8% of patients had an MPR ≥80%. The association between subjective and objective adherence was statistically significant (p = 0.004). Subjective adherence was associated with not skipping tamoxifen doses when feeling worse. Objective adherence was associated with having a stable job, not skipping tamoxifen doses when feeling worse, taking additional medications, and time on tamoxifen treatment. Fifty-six percent considered the information on tamoxifen to be insufficient and 37% not understandable. CONCLUSION: In our study, high subjective and objective adherence rates to adjuvant tamoxifen were reported, although an important proportion of women reported high rates of adverse effects and not fully understanding the benefits of tamoxifen. Strategies to increase tamoxifen adherence may be even more important now that longer durations of treatment or further ovarian function suppression have become the standard of care in YWBC.

2.
Rev Invest Clin ; 73(6): 347-353, 2021 11 05.
Artículo en Inglés | MEDLINE | ID: mdl-33053573

RESUMEN

BACKGROUND: In Mexico, up to 15% of breast cancer (BC) patients are 40 years or younger. Therefore, fertility preservation and pregnancy after cancer treatment are major concerns in this population. However, no data are available regarding Mexican physicians' knowledge and attitudes toward these issues. OBJECTIVE: The objective of the study was to describe physicians' attitudes, knowledge, and perceived barriers toward fertility preservation among young women with BC (YWBC) in a developing country. METHODS: A cross-sectional study was conducted among physicians attending the 2016 Mexican Society of Oncology (SMeO) Annual Meeting or affiliated to SMeO. Chi-squared tests were used to assess factors associated with a higher likelihood of disclosing infertility risks, discussing fertility preservation methods, referring to specialists, and effective counseling. RESULTS: Of the 314 participants, 83% reported a high sense of responsibility about informing treatment-related infertility risks, 58% always informed patients about those risks, 38% always discussed fertility preservation procedures, 52% always referred interested patients to fertility specialists, and 24% wrongly considered pregnancy and GnRH analogs detrimental in YWBC. Barriers for discussing fertility preservation were costs, lack of specialists, and prognosis. CONCLUSIONS: It is crucial to promote physicians' knowledge and to endorse policies to overcome barriers obstructing universal access to fertility preservation for YWBC in Mexico.

4.
JCO Glob Oncol ; 6: 395-406, 2020 03.
Artículo en Inglés | MEDLINE | ID: mdl-32142405

RESUMEN

PURPOSE: The pilot-phase report of the Joven & Fuerte prospective cohort broadly characterizes and assesses the needs of Mexican young women with breast cancer (YWBC). PATIENTS AND METHODS: Women age ≤ 40 years with nonmetastatic primary breast cancer were consecutively accrued from 2 hospitals. Data were collected at the first/baseline oncology visit and 2 years later using a sociodemographic survey, European Organisation for Research and Treatment of Cancer Quality-of-Life (QOL) Questionnaire Core 30 (QLQ-C30) and Breast Cancer-Specific QOL Questionnaire (QLQ-BR23), Hospital Anxiety and Depression Scale (HADS), Female Sexual Functioning Index (FSFI), Sexual Satisfaction Inventory, and patients' medical records. Pearson χ2 and 2-sided t tests were used for statistical analysis. An unadjusted P value < .05 was considered significant. RESULTS: Ninety patients were included, all with government health care coverage. Most had low monthly household incomes (98%) and at least a high school education (59%). There was a considerable prevalence of unpartnered patients (36%) and unmet parity (25%). Patients' most common initial symptom was a palpable mass (84%), and they were most frequently diagnosed with stage III disease (48%), with 51% having had a physician visit ≤ 3 months since detection but 39% receiving diagnosis > 12 months later. At baseline, 66% of patients were overweight/obese, and this proportion had significantly increased by 2 years (P < .001). Compared with baseline, global QLQ-C30 had improved significantly by 2 years (P = .004), as had HADS-Anxiety (P < .001). However, both at baseline and at 2 years, nearly half of patients exhibited FSFI sexual dysfunction. CONCLUSION: These preliminary findings demonstrate that YWBC in Mexico have particular sociodemographic and clinicopathologic characteristics, reinforcing the necessity to further describe and explore the needs of these young patients, because they may better represent the understudied and economically vulnerable population of YWBC in limited-resource settings.


Asunto(s)
Neoplasias de la Mama , Adulto , Neoplasias de la Mama/epidemiología , Femenino , Humanos , México/epidemiología , Estudios Prospectivos , Calidad de Vida , Encuestas y Cuestionarios
5.
Salud ment ; 42(3): 111-120, May.-Jun. 2019. tab, graf
Artículo en Inglés | LILACS-Express | LILACS | ID: biblio-1020917

RESUMEN

Abstract Introduction Little is known about how metabolic comorbidity affects stress response during breast cancer (BRCa) after a recent diagnosis. Objective To evaluate the physiological and psychological differences between the BRCa-RSxM groups and those with BRCa alone, and the influence of psychological variables and comorbidity in terms of stress response. Method Comparative non-experimental causal-descriptive study. Fifty patients recently diagnosed with BRCa (25 with BRCa and 25 with BRCa-RSxM) in a convenience sample participated. Frontal muscle activity and skin conductance were recorded in response to stressful conditions. Quality of life, perceived stress, and coping strategies scales were used. Results The presence of comorbidity (p = .001; p = .02), perceived stress (p = .004; p = .03), and social quality of life (p = .01; p = .01) influenced muscle activation and conductance during the emotional stressor (ES). Putting the stressful situation into perspective as a cognitive coping strategy was related to a decrease in activation (p = .04). An increase in physiological activation during the cognitive stressor (CS) was influenced by comorbidity (p = .05) and quality of social life (p = .01; p = .01). In turn, a decrease was influenced by the increase in age (p = .02). Discussion Physiological vulnerability, coping strategies (behavioral and cognitive), and prior learning influenced the resulting reaction during the stressful situation. Conclusion A metabolic disease, as a prelude to an oncological, may cause physiological vulnerability to respond adequately to stressful conditions.


Resumen Introducción Es poco lo que se sabe acerca de cómo afecta a una comorbilidad metabólica a la respuesta al estrés durante el cáncer de mama (CaMa) tras un diagnóstico reciente Objetivo Evaluar las diferencias fisiológicas y psicológicas entre los grupos de CaMa-RSxM y sólo con CaMa, y la influencia de las variables psicológicas y la comorbilidad en cuanto a la respuesta al estrés. Método Estudio no experimental descriptivo-causal comparativo. Participaron 50 pacientes con diagnóstico reciente de CaMa (25 en CaMa y 25 en CaMa-RSxM) en un muestreo por conveniencia. Se registraron la actividad muscular frontal y la conductancia de la piel frente a condiciones estresantes. Se aplicaron escalas de calidad de vida, estrés percibido y estrategias de afrontamiento. Resultados La presencia de la comorbilidad (p = .001; p = .02), estrés percibido (p = .004; p = .03) y la calidad de vida social (p = .01; p = .01) influyeron en la activación muscular y la conductancia durante el estresor emocional (EE). Poner en perspectiva la situación estresante como estrategia cognitiva de afrontamiento se relacionó con una disminución de la activación (p = .04). El aumento de activación fisiológica durante el estresor cognitivo (EC) estuvo influido por la comorbilidad (p = .05) y la calidad de vida social (p = .01; p = .01); a su vez, la disminución lo estuvo por el aumento en los años de edad (p = .02). Discusión La vulnerabilidad fisiológica, las estrategias de afrontamiento (conductuales y cognitivas) y el aprendizaje previo influyeron en la reacción resultante surgida durante la situación estresante. Conclusión Una enfermedad metabólica, como antesala de una oncológica, puede ocasionar vulnerabilidad fisiológica para responder adecuadamente a condiciones estresantes.

6.
Eur J Cancer Care (Engl) ; 28(4): e13040, 2019 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-31008546

RESUMEN

OBJECTIVE: To describe clinical and information needs, identify unmet support services and guide interventions for young breast cancer (BC) patients in Mexico. METHODS: Cross-sectional, qualitative study, using interpretive description methodology. Patients with initial BC diagnosis within 6-12 months prior to enrolment, ≤40 years old and literate were included in focus groups. RESULTS: Twenty-nine patients were included. Expressed needs were classified into the following categories: (a) understanding diagnosis and treatment; (b) treatment side effects; and (c) time, source and communication means. Patients felt their medical team did not provide enough information regarding diagnosis, treatment and relevant side effects related to fertility, menopause and sexuality. Lack of information fuelled uncertainty, distress, anxiety and fear, and could negatively influence treatment decisions. Patients wished that news be communicated considering their own attitude regarding the disease and providing psychological support when necessary, including partners, relatives and friends. They recommended that information should be delivered with an empathic and personalised approach, with take-home educational material to help them recall, comprehend and/or expand verbal information received during medical appointments. CONCLUSIONS: This study provides valuable insight to increase attention on unmet needs of young BC patients and to improve doctor-patient communication to ensure better care.


Asunto(s)
Neoplasias de la Mama/terapia , Evaluación de Necesidades , Educación del Paciente como Asunto , Adulto , Ansiedad , Comunicación , Comprensión , Estudios Transversales , Miedo , Femenino , Fertilidad , Grupos Focales , Humanos , Menopausia , México , Relaciones Médico-Paciente , Distrés Psicológico , Investigación Cualitativa , Sexualidad , Apoyo Social
7.
J Glob Oncol ; 4: 1-7, 2018 10.
Artículo en Inglés | MEDLINE | ID: mdl-30300053

RESUMEN

PURPOSE: Contraceptive counseling and adherence in young women with breast cancer (BC) is a relevant issue because chemotherapy and hormonal treatment resulting in amenorrhea do not preclude unintended pregnancies. Currently, there is limited evidence from high-income countries; however, there are no studies regarding use of contraceptives in patients with BC in Mexico. This study aimed to determine the rate of contraceptive use in young Mexican women with BC during cancer treatment, characterize their contraceptive preferences, and assess contraceptive counseling by Mexican physicians. PATIENTS AND METHODS: A cross-sectional survey was conducted regarding contraceptive use and counseling among women age 40 years or younger at BC diagnosis who had completed chemotherapy in the previous 5 years or who were currently receiving long-term treatment with hormonal therapy and/or trastuzumab at a large tertiary health care facility in Mexico. RESULTS: Of a total of 104 eligible women with median age at diagnosis of 34 years, 51.1% reported using a contraceptive during chemotherapy and 45.7% reported using a contraceptive during other types of cancer treatment (hormonal therapy and trastuzumab). Of the 51 patients (49%) who were sexually active during chemotherapy, 76.5% used contraception, but only 29.4% used an effective contraceptive method. When asked about contraceptive counseling, only 16.7% recalled being advised by their health care provider. Sexually active women who received contraceptive counseling used contraceptives more often than women who were not counseled (83.3% v 22.2%). CONCLUSION: A minority of young women with BC in Mexico use effective contraception methods during cancer treatment and receive contraceptive counseling. Informing all premenopausal patients with BC about effective use of contraception methods during treatment should be an essential aspect of the supportive care of young women.


Asunto(s)
Neoplasias de la Mama , Anticoncepción/estadística & datos numéricos , Adulto , Conducta Anticonceptiva , Anticonceptivos , Estudios Transversales , Femenino , Humanos , México , Adulto Joven
8.
Rev Invest Clin ; 69(4): 179-180, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-28776602

RESUMEN

Young women with breast cancer (BC) are a special population with distinctive genetic, clinical, and psychosocial features and requirements based on at least three considerations: (1) Cancer presentation at young age is often diagnosed at advanced stages, hence its prognosis is worse compared to their older counterparts1,2; (2) young BC patients often receive aggressive and prolonged systemic treatments that can be associated with significant long-term morbidity3; and (3) young women with BC experience substantial psychosocial vulnerability resulting from high levels of distress and depression associated with oncological interventions4. These factors pose complex issues for young patients with BC, particularly in regard to their family dynamics, social and professional lives, and self-development, thereby substantially undermining their quality of life.


Asunto(s)
Neoplasias de la Mama/psicología , Calidad de Vida , Adulto , Edad de Inicio , Neoplasias de la Mama/diagnóstico , Depresión/etiología , Depresión/psicología , Femenino , Humanos , Estadificación de Neoplasias , Pronóstico , Estrés Psicológico/etiología , Estrés Psicológico/psicología
9.
Rev Invest Clin ; 69(4): 181-192, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-28776603

RESUMEN

Young women with breast cancer (YWBC) represent roughly 15% of breast cancer (BC) cases in Latin America and other developing regions. Breast tumors occurring at an early age are more aggressive and have an overall worse prognosis compared to breast tumors in postmenopausal women. The expression of relevant proliferation biomarkers such as endocrine receptors and human epidermal growth factor receptor 2 appears to be unique in YWBC. Moreover, histopathological, molecular, genetic, and genomic studies have shown that YWBC exhibit a higher frequency of aggressive subtypes, differential tumor gene expression, increased genetic susceptibility, and specific genomic signatures, compared to older women with BC. This article reviews the current knowledge on tumor biology and genomic signatures in YWBC.


Asunto(s)
Biomarcadores de Tumor/genética , Neoplasias de la Mama/patología , Predisposición Genética a la Enfermedad , Adulto , Edad de Inicio , Neoplasias de la Mama/epidemiología , Neoplasias de la Mama/genética , ADN , Femenino , Regulación Neoplásica de la Expresión Génica , Humanos , América Latina/epidemiología , Biología Molecular , Mutación , Pronóstico
10.
Rev Invest Clin ; 69(4): 223-228, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-28776607

RESUMEN

Despite the high rates of breast cancer among young Mexican women, their special needs and concerns have not been systematically addressed. To fulfill these unsatisfied demands, we have developed "Joven & Fuerte: Program for Young Women with Breast Cancer in Mexico," the first program dedicated to the care of young breast cancer patients in Latin America, which is taking place at the National Cancer Institute of Mexico and the two medical facilities of the Instituto Tecnológico y de Estudios Superiores de Monterrey. The program was created to optimize the complex clinical and psychosocial care of these patients, enhance education regarding their special needs, and promote targeted research, as well as to replicate this program model in other healthcare centers across Mexico and Latin America. From November 2013 to February 2017, the implementation of the "Joven & Fuerte" program has delivered specialized care to 265 patients, through the systematic identification of their particular needs and the provision of fertility, genetic, and psychological supportive services. Patients and families have engaged in pedagogic activities and workshops and have created a motivated and empowered community. The program developed and adapted the first educational resources in Spanish dedicated for young Mexican patients, as well as material for healthcare providers. As for research, a prospective cohort of young breast cancer patients was established to characterize clinicopathological features and psychosocial effects at baseline and during follow-up, as a guide for the development of specific cultural interventions addressing this vulnerable group. Eventually, it is intended that the program's organization and structure can reach national and international interactions and serve as a platform for other countries.


Asunto(s)
Neoplasias de la Mama/terapia , Atención a la Salud/organización & administración , Necesidades y Demandas de Servicios de Salud , Adulto , Edad de Inicio , Neoplasias de la Mama/epidemiología , Neoplasias de la Mama/psicología , Femenino , Humanos , México , Educación del Paciente como Asunto , Desarrollo de Programa , Apoyo Social
11.
Rev Invest Clin ; 69(2): 57-58, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-28453503

RESUMEN

Breast cancer (BC) is the most frequently diagnosed malignancy in young women and is the leading cause of cancer-related mortality in this age group. This issue represents a major public health problem in developing countries, where the incidence of BC is rapidly increasing and where young women represent a higher proportion of the total BC patient population compared to developed countries. In Latin America, BC among women aged 40 years or less accounts for up to 11% of new BC cases and 7% of all BC deaths. In Mexico, a very high proportion of the total number of BC patients are diagnosed in their early years, reaching up to 15% in some healthcare institutions.


Asunto(s)
Neoplasias de la Mama/epidemiología , Países en Desarrollo , Adulto , Factores de Edad , Neoplasias de la Mama/diagnóstico , Femenino , Humanos , Estadificación de Neoplasias
12.
Breast ; 33: 71-75, 2017 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-28284061

RESUMEN

OBJECTIVE: Young women represent a high proportion of the total number of breast cancer (BC) patients in Mexico; however, no previous studies addressing their attitudes regarding the risk of chemotherapy-induced infertility and its contributing factors are available. The aim of this study was to evaluate the concerns of young women with BC towards the risk of infertility in two referral centers in Mexico with access to public health services. METHODS: A cross-sectional study including women with newly or previously detected BC aged 40 years or younger at diagnosis was conducted. Variables regarding concerns about fertility were collected from an adapted version of the Fertility Issues Survey. RESULTS: 134 consecutive eligible women responded to the in-person paper survey. 55% were partnered, 35.1% had no children, and 48% reported willingness to have children prior to BC diagnosis. Only 3% of patients considered to be able to afford extra expenses. At diagnosis, 44% of women expressed some level of concern about infertility risk. The only factor significantly associated with fertility concern was the desire of having children prior to diagnosis (OR 11.83, p = 0.006). Only 30.6% patients recalled having received information regarding infertility risk from their physicians. CONCLUSION: A minority of young women with breast cancer in Mexico is informed about the risk of BC treatment-induced infertility, despite substantial interest. Informing all patients about infertility risk and available options for fertility preservation should be an essential aspect of the supportive care of young women with BC, even in low-middle income countries such as Mexico.


Asunto(s)
Antineoplásicos/efectos adversos , Neoplasias de la Mama/psicología , Infertilidad Femenina/psicología , Adulto , Neoplasias de la Mama/tratamiento farmacológico , Estudios Transversales , Femenino , Preservación de la Fertilidad/psicología , Humanos , Infertilidad Femenina/inducido químicamente , México , Encuestas y Cuestionarios , Adulto Joven
13.
BMC Cancer ; 16(1): 740, 2016 09 20.
Artículo en Inglés | MEDLINE | ID: mdl-27645148

RESUMEN

BACKGROUND: It has become evident that intra-tumor heterogeneity of breast cancer impact on several biological processes such as proliferation, migration, cell death and also might contribute to chemotherapy resistance. The expression of Receptor Tyrosine Kinases (RTKs) has not been analyzed in the context of intra-tumor heterogeneity in a primary breast cancer cell culture. Several subpopulations were isolated from the MBCDF (M serial-breast cancer ductal F line) primary breast cancer cells and were successfully maintained in culture and divided in two groups according to their morphology and RTKs expression pattern, and correlated with biological processes like proliferation, migration, anchorage-independent cell growth, and resistance to cytotoxic chemotherapy drugs and tyrosine kinase inhibitors (TKIs). METHODS: Subpopulations were isolated from MBCDF primary breast cancer cell culture by limiting dilution. RTKs and hormone receptors were examined by Western blot. Proliferation was measure by 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide (MTT assay). Cell viability was evaluated by Crystal Violet. Migration was assessed using Boyden chambers. Anchorage-independent cell growth was evaluated by colony formation in soft agar. RESULTS: Several subpopulations were isolated from the MBCDF breast cancer cells that were divided into two groups according to their morphology. Analysis of RTKs expression pattern showed that HER1, HER3, c-Met and VEGFR2 were expressed exclusively in cells from group 1, but not in cells from group 2. PDGFR was expressed only in cells from group 2, but not in cells from group 1. HER2, HER4, c-Kit, IGF1-R were expressed in all subpopulations. Biological processes correlated with the RTKs expression pattern. Group 2 subpopulations present the highest rate of cell proliferation, migration and anchorage-independent cell growth. Analysis of susceptibility to chemotherapy drugs and TKIs showed that only Paclitaxel and Imatinib behaved differently between groups. Group 1-cells were resistant to both Paclitaxel and Imatinib. CONCLUSIONS: We demonstrated that subpopulations from MBCDF primary cell culture could be divided into two groups according to their morphology and a RTKs excluding-expression pattern. The differences observed in RTKs expression correlate with the biological characteristics and chemoresistance of each group. These results suggest that intra-tumor heterogeneity contributes to generate groups of subpopulations with a more aggressive phenotype within the tumor.


Asunto(s)
Neoplasias de la Mama/patología , Mesilato de Imatinib/farmacología , Paclitaxel/farmacología , Cultivo Primario de Células/métodos , Proteínas Tirosina Quinasas Receptoras/metabolismo , Neoplasias de la Mama/genética , Neoplasias de la Mama/metabolismo , Movimiento Celular/efectos de los fármacos , Proliferación Celular/efectos de los fármacos , Supervivencia Celular/efectos de los fármacos , Resistencia a Antineoplásicos , Femenino , Regulación Neoplásica de la Expresión Génica/efectos de los fármacos , Heterogeneidad Genética , Humanos , Proteínas Tirosina Quinasas Receptoras/genética , Células Tumorales Cultivadas
14.
Arch. latinoam. nutr ; 64(3): 153-160, sep. 2014. ilus, tab
Artículo en Inglés | LILACS | ID: lil-752694

RESUMEN

The iodine nutritional status of a population is mainly measured by urinary iodine excretion (UI) and thyroid volume determined by ultrasound (US). The surveillance of nutritional iodine levels in the Mexican population has been insufficient. Our aim was to determine the UI in random samples from adults living in an urban area. We selected a sample of healthy individuals over the age of 18 that were students, physicians or administrative personnel at our Institution and had no known thyroid disease. Thyroid volume was determined by ultrasound in all volunteers as well as thyroid hormones and antithyroid antibodies and a urine sample was obtained. One hundred and two volunteers with a median age of 29, participated in the study. The group’s median UI was 221 μg/L,interquartile range (IQR)(135.0 to 356.8) and no differences were observed between genders: women had a UI of 218.0 μg/L IQR (129.0 a 351.0) vs. 223.0 μg/L IQR (138.0 to 374.0) in males, p 0.941. Excessive dietary iodine intake was established in 31.4% of all volunteers according to their UI, placing them at risk of thyroid dysfunction. It is fundamental to evaluate the national iodine nutritional status in Mexico. We discuss the current status of the nutritional state in the Americas, emphasizing that in Latin America and the observed tendency in the region to ingest a diet high in iodine.


El estatus nutricional del yodo en una población, principalmente es medido por la excreción del yodo urinario (UI) y el cálculo del volumen tiroideo por ultrasonido (US). La vigilancia nutricional del yodo en la población en México ha sido escasa. El objetivo fue determinar la UI en una muestra casual en adultos sanos que habitan en un área urbana. Se seleccionó una muestra de individuos mayores de 18 años, entre estudiantes, médicos y trabajadores administrativos de nuestra institución, sanos, sin enfermedad tiroidea conocida. A todos los voluntarios se les determinó el volumen tiroideo por US, hormonas y anticuerpos antitiroideos y se les solicitó una muestra de orina. Participaron 102 voluntarios, mediana de 29 años. La mediana de la UI del grupo fue 221 μg/L, rango intercuartílico (RIQ) (135.0 a 356.8), no hubo diferencias entre géneros, las mujeres tuvieron una UI de, 218.0 μg/L RIQ (129.0 a 351.0) vs 223.0 μg/L RIQ (138.0 a 374.0) p 0.941. El 31.4% de los voluntarios mostraron una ingestión excesiva de yodo en la dieta de acuerdo a la UI, lo cual los coloca en riesgo de sufrir disfunción tiroidea. Es necesario considerar la evaluación Nacional del estatus nutricional del yodo, en México. En el artículo se discute la situación actual del estatus nutricional en las Américas, haciendo énfasis en Latinoamérica y a la tendencia de la región a la dieta excedida en yodo.


Asunto(s)
Adulto , Femenino , Humanos , Masculino , Conducta Alimentaria , Yodo/orina , Glándula Tiroides , Hormonas Tiroideas/sangre , Estudios Transversales , Encuestas sobre Dietas , Estado de Salud , Yodo/administración & dosificación , México , Cloruro de Sodio Dietético/administración & dosificación , Población Urbana
15.
Arch Latinoam Nutr ; 64(3): 153-60, 2014 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-26137791

RESUMEN

The iodine nutritional status of a population is mainly measured by urinary iodine excretion (UI) and thyroid volume determined by ultrasound (US). The surveillance of nutritional iodine levels in the Mexican population has been insufficient. Our aim was to determine the UI in random samples from adults living in an urban area. We selected a sample of healthy individuals over the age of 18 that were students, physicians or administrative personnel at our Institution and had no known thyroid disease. Thyroid volume was determined by ultrasound in all volunteers as well as thyroid hormones and antithyroid antibodies and a urine sample was obtained. One hundred and two volunteers with a median age of 29, participated in the study. The group's median UI was 221 µg/L, interquartile range (IQR) (135.0 to 356.8) and no differences were observed between genders: women had a UI of 218.0 µg/L IQR (129.0 a 351.0) vs. 223.0 µg/L IQR (138.0 to 374.0) in males, p 0.941. Excessive dietary iodine intake was established in 31.4% of all volunteers according to their UI, placing them at risk of thyroid dysfunction. It is fundamental to evaluate the national iodine nutritional status in Mexico. We discuss the current status of the nutritional state in the Americas, emphasizing that in Latin America and the observed tendency in the region to ingest a diet high in iodine.


Asunto(s)
Conducta Alimentaria , Yodo/orina , Glándula Tiroides/diagnóstico por imagen , Hormonas Tiroideas/sangre , Adulto , Estudios Transversales , Encuestas sobre Dietas , Femenino , Estado de Salud , Humanos , Yodo/administración & dosificación , Masculino , México , Cloruro de Sodio Dietético/administración & dosificación , Ultrasonografía , Población Urbana
16.
Med Oncol ; 28(4): 973-80, 2011 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-20517658

RESUMEN

The purpose of this study was to compare the outcome and resectability of patients with gastric cancer recurrence after curative surgery detected by follow-up endoscopy, according to the presence or absence of symptoms. All patients with gastric carcinoma, who underwent a curative gastrectomy, were retrospectively identified. We analyzed outcome and survival in patients compliant with routine follow-up who presented symptomatic and asymptomatic recurrence. Of the 119 resected patients, 63.0% had a recurrence, with an overall survival of 20.0 months. Fourteen patients were asymptomatic when recurrence was detected, whereas 61 patients were symptomatic. Median time to recurrence was 16.0 m for both groups. A local curative re-resection was possible in 2/14 (asymptomatic) and 1/61 (symptomatic). Asymptomatic patients had a longer median postrecurrence survival time of 9.0 months, compared with 2.0 months in the symptomatic patients (p=0.034). The median overall survival was greater in the asymptomatic vs symptomatic group (25.0 vs 20.0 months), although this did not reach statistical significance. The results from this study advocate that the presence or absence of symptoms is a good surrogate marker to assess biologic aggressiveness. The value of routine follow-up endoscopy to permit a higher rate of re-resection in asymptomatic patients remains to be established.


Asunto(s)
Adenocarcinoma/patología , Recurrencia Local de Neoplasia/mortalidad , Neoplasias Gástricas/patología , Adenocarcinoma/mortalidad , Adenocarcinoma/cirugía , Adulto , Anciano , Anciano de 80 o más Años , Femenino , Gastrectomía , Humanos , Estimación de Kaplan-Meier , Masculino , Persona de Mediana Edad , Recurrencia Local de Neoplasia/patología , Recurrencia Local de Neoplasia/cirugía , Estadificación de Neoplasias , Estudios Retrospectivos , Neoplasias Gástricas/mortalidad , Neoplasias Gástricas/cirugía , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...